

Vimal K Derebail

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6062571/publications.pdf>

Version: 2024-02-01

90
papers

2,603
citations

186265

28
h-index

197818

49
g-index

98
all docs

98
docs citations

98
times ranked

3282
citing authors

#	ARTICLE	IF	CITATIONS
1	The nephropathy of sickle cell trait and sickle cell disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 361-377.	9.6	26
2	Black and White Adults With CKD Hospitalized With Acute Kidney Injury: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2022, , .	1.9	1
3	Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study. <i>British Journal of Haematology</i> , 2022, , .	2.5	0
4	Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis. <i>Blood Advances</i> , 2022, 6, 4461-4470.	5.2	5
5	Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies. <i>Nephron</i> , 2021, 145, 245-255.	1.8	8
6	Should PLEX Be Used for Severe AKI and/or Pulmonary Hemorrhage in ANCA-Associated Vasculitis (AAV)? PRO. <i>Kidney360</i> , 2021, 2, 776-778.	2.1	1
7	Subfertility and early menopause in women with glomerular disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 948-950.	0.7	4
8	Treatment Updates in Antineutrophil Cytoplasmic Autoantibodies (ANCA) Vasculitis. <i>Kidney360</i> , 2021, 2, 763-770.	2.1	16
9	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. <i>Pediatric Nephrology</i> , 2021, 36, 2747-2757.	1.7	3
10	Sparkling myocardium in a hemodialysis patient. <i>Kidney International</i> , 2021, 99, 1028.	5.2	0
11	Association of Lupus Nephritis Histopathologic Classification With Venous Thromboembolismâ€™ Modification by Age at Biopsy. <i>Kidney International Reports</i> , 2021, 6, 1653-1660.	0.8	2
12	Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review. <i>Kidney Medicine</i> , 2021, 3, 607-618.	2.0	14
13	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907.	0.8	8
14	Longitudinal study of glomerular hyperfiltration and normalization of estimated glomerular filtration in adults with sickle cell disease. <i>British Journal of Haematology</i> , 2021, 195, 123-132.	2.5	7
15	Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals. <i>JAMA Network Open</i> , 2021, 4, e2030435.	5.9	5
16	Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity. <i>Journal of Immunotherapy</i> , 2021, 44, 127-131.	2.4	19
17	Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. <i>Haematologica</i> , 2021, 106, 1749-1753.	3.5	11
18	Role of direct oral anticoagulants in patients with kidney disease. <i>Kidney International</i> , 2020, 97, 664-675.	5.2	35

#	ARTICLE	IF	CITATIONS
19	The Authors Reply. <i>Kidney International Reports</i> , 2020, 5, 1612-1613.	0.8	0
20	Contraceptive Use and Elective Terminations in Women Enrolled in the Glomerular Disease Collaborative Network. <i>Kidney International Reports</i> , 2020, 5, 1780-1783.	0.8	2
21	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 597-606.	2.9	14
22	Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 706-717.	0.8	8
23	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
24	ANCA-Associated Vasculitis – Refining Therapy with Plasma Exchange and Glucocorticoids. <i>New England Journal of Medicine</i> , 2020, 382, 671-673.	27.0	43
25	Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. <i>RMD Open</i> , 2020, 6, e001490.	3.8	17
26	Incidence and prediction of checkpoint inhibitor immune-related nephrotoxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 91-91.	1.6	0
27	Vasculitides. , 2019, , 223-228.		0
28	A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E299-E301.	4.1	6
29	Association of sickle cell trait with measures of cognitive function and dementia in African Americans. <i>ENeurologicalSci</i> , 2019, 16, 100201.	1.3	3
30	Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study. <i>American Journal of Hematology</i> , 2019, 94, 1306-1313.	4.1	9
31	Elevated Microparticle Tissue Factor Activity Differentiates Patients With Venous Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis. <i>Kidney International Reports</i> , 2019, 4, 1617-1629.	0.8	20
32	Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality. <i>British Journal of Haematology</i> , 2019, 186, 900-907.	2.5	12
33	Glomerular Filtration: Too Much of a Good Thing?. <i>American Journal of Kidney Diseases</i> , 2019, 73, 756-758.	1.9	0
34	Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 47-55.	1.9	37
35	The Sickle Cell Disease Ontology: enabling universal sickle cell-based knowledge representation. Database: the <i>Journal of Biological Databases and Curation</i> , 2019, .	3.0	14
36	Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease. <i>British Journal of Haematology</i> , 2019, 184, 246-252.	2.5	20

#	ARTICLE	IF	CITATIONS
37	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	1.9	68
38	Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. <i>Journal of Nephrology</i> , 2019, 32, 669-672.	2.0	14
39	The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST). <i>Blood</i> , 2019, 134, 1018-1018.	1.4	3
40	Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia. <i>Blood</i> , 2019, 134, 2308-2308.	1.4	1
41	Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia. <i>Blood</i> , 2019, 134, 2268-2268.	1.4	2
42	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2745-2754.	6.1	128
43	Rapid Decline in Kidney Function in Sickle Cell Disease. <i>Blood</i> , 2018, 132, 1084-1084.	1.4	0
44	Association of Sickle Cell Trait with Measures of Cognitive Function and Dementia in African Americans. <i>Blood</i> , 2018, 132, 1099-1099.	1.4	0
45	A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 399-407.	4.5	69
46	Sickle Cell Trait and the Risk of ESRD in Blacks. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2180-2187.	6.1	79
47	Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). <i>Kidney International Reports</i> , 2017, 2, 654-664.	0.8	36
48	Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function. <i>Blood</i> , 2017, 129, 799-801.	1.4	10
49	The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait. <i>Expert Review of Hematology</i> , 2017, 10, 1087-1094.	2.2	41
50	Renal Medullary Carcinoma: Establishing Standards in Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 414-421.	2.5	52
51	Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1752-1759.	4.5	41
52	Patients with primary membranous nephropathy are at high risk of cardiovascular events. <i>Kidney International</i> , 2016, 89, 1111-1118.	5.2	55
53	Association of Sickle Cell Trait with Risk of Coronary Heart Disease in African Americans. <i>Blood</i> , 2016, 128, 11-11.	1.4	3
54	Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia. <i>PLoS ONE</i> , 2016, 11, e0162652.	2.5	27

#	ARTICLE	IF	CITATIONS
55	Progression of Chronic Kidney Disease in Sickle Cell Disease. <i>Blood</i> , 2016, 128, 1323-1323.	1.4	3
56	Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory. <i>British Journal of Haematology</i> , 2015, 170, 5-14.	2.5	46
57	Polyomavirus Nephropathy. <i>Transplantation</i> , 2015, 99, 609-615.	1.0	38
58	Prospective study of sickle cell trait and venous thromboembolism incidence. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2-9.	3.8	113
59	Endothelin-1 Is Associated with Albuminuria and Measures of Vascular Endothelial Dysfunction in Sickle Cell Anemia. <i>Blood</i> , 2015, 126, 983-983.	1.4	12
60	HemoglobinA2 Levels Associate with Lower ESA-Dose in African-Americans with Sickle Cell Trait and End-Stage Kidney Disease. <i>Blood</i> , 2015, 126, 3407-3407.	1.4	0
61	Albuminuria Is Associated with Endothelial Dysfunction in Sickle Cell Disease. <i>Blood</i> , 2015, 126, 2186-2186.	1.4	6
62	Association of Hemoglobin S and C Traits with Kidney Disease in African Americans in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Blood</i> , 2015, 126, 70-70.	1.4	0
63	Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. <i>Kidney International</i> , 2014, 85, 1412-1420.	5.2	76
64	Association of Sickle Cell Trait With Chronic Kidney Disease and Albuminuria in African Americans. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2115.	7.4	167
65	Sickle Trait in African-American Hemodialysis Patients and Higher Erythropoiesis-Stimulating Agent Dose. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 819-826.	6.1	14
66	Sickle Cell Trait and Incident Ischemic Stroke in the Atherosclerosis Risk in Communities Study. <i>Stroke</i> , 2014, 45, 2863-2867.	2.0	51
67	Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1211-1218.	0.7	64
68	Sickle Cell Nephropathy. , 2014, , 357-361.		0
69	Adenovirus causing fever, upper respiratory infection, and allograft nephritis complicated by persistent asymptomatic viremia. <i>Transplant Infectious Disease</i> , 2014, 16, 648-652.	1.7	27
70	Predictors of Treatment Outcomes in ANCA-Associated Vasculitis with Severe Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 905-913.	4.5	120
71	The glomerulopathy of sickle cell disease. <i>American Journal of Hematology</i> , 2014, 89, 907-914.	4.1	100
72	Venous Thromboembolism in Patients with Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 43-51.	4.5	173

#	ARTICLE	IF	CITATIONS
73	Diagnostic Significance of Peritubular Capillary Basement Membrane Multilaminations in Kidney Allografts. <i>Transplantation</i> , 2012, 94, 620-629.	1.0	41
74	Vasculitides. , 2012, , 271-277.		0
75	Erythrocyte Adhesion in Hemodialysis Patients â€œ A Novel Potential Contributor to Inflammation in End-Stage Renal Disease.. <i>Blood</i> , 2012, 120, 2092-2092.	1.4	0
76	Hydroxyurea Is Associated with Lower Prevalence of Albuminuria in Adults with Sickle Cell Disease. <i>Blood</i> , 2012, 120, 3211-3211.	1.4	0
77	Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. <i>Kidney International</i> , 2011, 80, 1339-1343.	5.2	35
78	Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. <i>Kidney International</i> , 2011, 80, 992-999.	5.2	12
79	The Authors Reply:. <i>Kidney International</i> , 2010, 78, 708-709.	5.2	3
80	78: Variant Hemoglobin May Affect Erythropoietin Response in African-Americans Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2010, 55, B51.	1.9	0
81	Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. <i>Kidney International</i> , 2010, 77, 609-616.	5.2	124
82	High Prevalence of Sickle Cell Trait in African Americans with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 413-417.	6.1	70
83	Sickle-Cell Trait: Novel Clinical Significance. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 418-422.	2.5	90
84	Increased Red Cell Phosphatidylserine Exposure Correlates with Enhanced Thrombin Generation In Sickle Trait Patients with End Stage Renal Disease. <i>Blood</i> , 2010, 116, 2665-2665.	1.4	3
85	The Case â€¦ Acute kidney injury in a patient with P. carinii pneumonia. <i>Kidney International</i> , 2009, 75, 865-866.	5.2	0
86	Rituximab Therapy for Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 734-744.	4.5	80
87	A rare cause of the pulmonary-renal syndrome: a case of atypical haemolytic-uraemic syndrome complicated by pulmonary haemorrhage. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 417-419.	2.9	5
88	Combined effects of AT1 and ETA receptor antagonists, candesartan, and A-127722 in DOCAâ€œsalt hypertensive rats. <i>General Pharmacology</i> , 2000, 34, 337-342.	0.7	17
89	Vascular Diseases of the Kidney. , 0, , .		0
90	Hyperkalemia and Metabolic Acidosis Occur at Higher Estimated Glomerular Filtration Rates in Sickle Cell Disease. <i>Kidney360</i> , 0, , 10.34067/KID.0006802021.	2.1	3